Combined Reduced Fluence Photodynamic Therapy and Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy
Ricci F et al. – Reduced fluence photodynamic therapy (PDT) limits laser exposure, minimizing the risks of PDT–induced adverse effects. Intravitreal injections of ranibizumab 0.5 mg reduced bleeding and leakage in polypoidal choroidal vasculopathy eyes and interfere with rebound upregulation of vascular endothelial growth factor because of PDT–induced choroidal hypoperfusion. Combined treatment may improve treatment outcomes in polypoidal choroidal vasculopathy while minimizing ocular and systemic complications of treatment.